Literature DB >> 18789655

Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis.

Hae-Seong Nam, Won-Jung Koh, O Jung Kwon, Sang-Nae Cho, Tae Sun Shim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18789655     DOI： 10.1016/j.ijantimicag.2008.06.014

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


× No keyword cloud information.
  13 in total

1.  Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.

Authors:  Robert S Wallis; Wesley Jakubiec; Vikas Kumar; Gabriella Bedarida; Annette Silvia; Darcy Paige; Tong Zhu; Mark Mitton-Fry; Lynn Ladutko; Sheldon Campbell; Paul F Miller
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.

Authors:  J W C Alffenaar; T van der Laan; S Simons; T S van der Werf; P J van de Kasteele; H de Neeling; D van Soolingen
Journal:  Antimicrob Agents Chemother       Date:  2011-01-03       Impact factor: 5.191

3.  Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Xin Zhang; Matthew E Falagas; Konstantinos Z Vardakas; Rui Wang; Rong Qin; Jin Wang; Youning Liu
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

Review 4.  World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?

Authors:  Kelly E Dooley; Ekwaro A Obuku; Nadza Durakovic; Vera Belitsky; Carole Mitnick; Eric L Nuermberger
Journal:  J Infect Dis       Date:  2012-07-17       Impact factor: 5.226

Review 5.  Current development and future prospects in chemotherapy of tuberculosis.

Authors:  Eric L Nuermberger; Melvin K Spigelman; Wing Wai Yew
Journal:  Respirology       Date:  2010-06-04       Impact factor: 6.424

Review 6.  Antituberculosis therapy for 2012 and beyond.

Authors:  Michael Lauzardo; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2012-02-15       Impact factor: 3.889

7.  Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.

Authors:  Jan-Willem C Alffenaar; Richard van Altena; Ilse M Harmelink; Patricia Filguera; Esther Molenaar; A Mireille A Wessels; Dick van Soolingen; Jos G W Kosterink; Donald R A Uges; Tjip S van der Werf
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

Review 8.  WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis.

Authors:  Kwok-Chiu Chang; Wing-Wai Yew; Cheuk-Ming Tam; Chi-Chiu Leung
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

9.  Assessment of linezolid efficacy, safety and tolerability in the treatment of tuberculosis: A retrospective case review.

Authors:  Alena Tse-Chang; Dennis Kunimoto; Evelina Der; Rabia Ahmed
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

10.  Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis.

Authors:  Kristina M Bigelow; Amelia N Deitchman; Si-Yang Li; Kala Barnes-Boyle; Sandeep Tyagi; Heena Soni; Kelly E Dooley; Rada M Savic; Eric L Nuermberger
Journal:  J Infect Dis       Date:  2021-06-04       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.